Swiss Secondary Prevention and Rehabilitation Registry
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Aug 10, 2022
Trial Information
Current as of June 09, 2025
Recruiting
Keywords
ClinConnect Summary
The Swiss Secondary Prevention and Rehabilitation Registry (SwissPR) is a clinical trial aimed at improving the care of people with cardiovascular diseases (CVD). The study will track the characteristics and health outcomes of patients who are taking part in a 12-week outpatient rehabilitation program. This means that participants will receive support and guidance to help them recover and manage their heart health while continuing their daily routines.
To join the study, participants must be enrolled in the outpatient rehabilitation program and provide written consent to take part. The trial is open to people of all ages and genders, but those who cannot follow the program for more than three weeks, are not willing to give consent, or have difficulty understanding the consent process may not be eligible. By participating, individuals can expect to contribute to valuable research that aims to enhance treatment and support for others with similar health issues in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participation in an ambulatory CR program (all age groups)
- • Written informed consent
- Exclusion Criteria:
- • Inability to follow an ambulatory CR program more than 3 weeks
- • Not willing to give informed consent
- • Inability to understand the informed consent due to language comprehension
- • Lack of discernment
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Patients applied
Trial Officials
Otmar Pfister, Prof. Dr. med.
Principal Investigator
Outpatient Cardiology, University Hospital Basel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials